FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice

Sun Young Lee, Roland Meier, Saori Furuta, Marc E. Lenburg, Paraic A. Kenny, Ren Xu, Mina J. Bissell

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Breast cancers commonly become resistant to EGFR-tyrosine kinase inhibitors (EGFR-TKIs); however, the mechanisms of this resistance remain largely unknown. We hypothesized that resistance may originate, at leastin part, from molecular alterations that activate signaling downstream of EGFR. Using a screen to measurereversion of malignant cells into phenotypically nonmalignant cells in 3D gels, we identified FAM83A as a candidatecancer-associated gene capable of conferring resistance to EGFR-TKIs. FAM83A overexpression in cancercells increased proliferation and invasion and imparted EGFR-TKI resistance both in cultured cells and inanimals. Tumor cells that survived EGFR-TKI treatment in vivo had upregulated FAM83A levels. Additionally,FAM83A overexpression dramatically increased the number and size of transformed foci in cultured cells andanchorage-independent growth in soft agar. Conversely, FAM83A depletion in cancer cells caused reversionof the malignant phenotype, delayed tumor growth in mice, and rendered cells more sensitive to EGFR-TKI.Analyses of published clinical data revealed a correlation between high FAM83A expression and breast cancerpatients' poor prognosis. We found that FAM83A interacted with and caused phosphorylation of c-RAF andPI3K p85, upstream of MAPK and downstream of EGFR. These data provide an additional mechanism bywhich tumor cells can become EGFR-TKI resistant.

Original languageEnglish (US)
Pages (from-to)3211-3220
Number of pages10
JournalJournal of Clinical Investigation
Volume122
Issue number9
DOIs
StatePublished - Sep 4 2012

Fingerprint

Protein-Tyrosine Kinases
Breast Neoplasms
Cultured Cells
Neoplasms
Growth
Agar
Breast
Gels
Phosphorylation
Phenotype
Genes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Lee, S. Y., Meier, R., Furuta, S., Lenburg, M. E., Kenny, P. A., Xu, R., & Bissell, M. J. (2012). FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice. Journal of Clinical Investigation, 122(9), 3211-3220. https://doi.org/10.1172/JCI60498

FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice. / Lee, Sun Young; Meier, Roland; Furuta, Saori; Lenburg, Marc E.; Kenny, Paraic A.; Xu, Ren; Bissell, Mina J.

In: Journal of Clinical Investigation, Vol. 122, No. 9, 04.09.2012, p. 3211-3220.

Research output: Contribution to journalArticle

Lee, SY, Meier, R, Furuta, S, Lenburg, ME, Kenny, PA, Xu, R & Bissell, MJ 2012, 'FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice', Journal of Clinical Investigation, vol. 122, no. 9, pp. 3211-3220. https://doi.org/10.1172/JCI60498
Lee SY, Meier R, Furuta S, Lenburg ME, Kenny PA, Xu R et al. FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice. Journal of Clinical Investigation. 2012 Sep 4;122(9):3211-3220. https://doi.org/10.1172/JCI60498
Lee, Sun Young ; Meier, Roland ; Furuta, Saori ; Lenburg, Marc E. ; Kenny, Paraic A. ; Xu, Ren ; Bissell, Mina J. / FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice. In: Journal of Clinical Investigation. 2012 ; Vol. 122, No. 9. pp. 3211-3220.
@article{7f32e45159df47f68663f9123b022413,
title = "FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice",
abstract = "Breast cancers commonly become resistant to EGFR-tyrosine kinase inhibitors (EGFR-TKIs); however, the mechanisms of this resistance remain largely unknown. We hypothesized that resistance may originate, at leastin part, from molecular alterations that activate signaling downstream of EGFR. Using a screen to measurereversion of malignant cells into phenotypically nonmalignant cells in 3D gels, we identified FAM83A as a candidatecancer-associated gene capable of conferring resistance to EGFR-TKIs. FAM83A overexpression in cancercells increased proliferation and invasion and imparted EGFR-TKI resistance both in cultured cells and inanimals. Tumor cells that survived EGFR-TKI treatment in vivo had upregulated FAM83A levels. Additionally,FAM83A overexpression dramatically increased the number and size of transformed foci in cultured cells andanchorage-independent growth in soft agar. Conversely, FAM83A depletion in cancer cells caused reversionof the malignant phenotype, delayed tumor growth in mice, and rendered cells more sensitive to EGFR-TKI.Analyses of published clinical data revealed a correlation between high FAM83A expression and breast cancerpatients' poor prognosis. We found that FAM83A interacted with and caused phosphorylation of c-RAF andPI3K p85, upstream of MAPK and downstream of EGFR. These data provide an additional mechanism bywhich tumor cells can become EGFR-TKI resistant.",
author = "Lee, {Sun Young} and Roland Meier and Saori Furuta and Lenburg, {Marc E.} and Kenny, {Paraic A.} and Ren Xu and Bissell, {Mina J.}",
year = "2012",
month = "9",
day = "4",
doi = "10.1172/JCI60498",
language = "English (US)",
volume = "122",
pages = "3211--3220",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "9",

}

TY - JOUR

T1 - FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice

AU - Lee, Sun Young

AU - Meier, Roland

AU - Furuta, Saori

AU - Lenburg, Marc E.

AU - Kenny, Paraic A.

AU - Xu, Ren

AU - Bissell, Mina J.

PY - 2012/9/4

Y1 - 2012/9/4

N2 - Breast cancers commonly become resistant to EGFR-tyrosine kinase inhibitors (EGFR-TKIs); however, the mechanisms of this resistance remain largely unknown. We hypothesized that resistance may originate, at leastin part, from molecular alterations that activate signaling downstream of EGFR. Using a screen to measurereversion of malignant cells into phenotypically nonmalignant cells in 3D gels, we identified FAM83A as a candidatecancer-associated gene capable of conferring resistance to EGFR-TKIs. FAM83A overexpression in cancercells increased proliferation and invasion and imparted EGFR-TKI resistance both in cultured cells and inanimals. Tumor cells that survived EGFR-TKI treatment in vivo had upregulated FAM83A levels. Additionally,FAM83A overexpression dramatically increased the number and size of transformed foci in cultured cells andanchorage-independent growth in soft agar. Conversely, FAM83A depletion in cancer cells caused reversionof the malignant phenotype, delayed tumor growth in mice, and rendered cells more sensitive to EGFR-TKI.Analyses of published clinical data revealed a correlation between high FAM83A expression and breast cancerpatients' poor prognosis. We found that FAM83A interacted with and caused phosphorylation of c-RAF andPI3K p85, upstream of MAPK and downstream of EGFR. These data provide an additional mechanism bywhich tumor cells can become EGFR-TKI resistant.

AB - Breast cancers commonly become resistant to EGFR-tyrosine kinase inhibitors (EGFR-TKIs); however, the mechanisms of this resistance remain largely unknown. We hypothesized that resistance may originate, at leastin part, from molecular alterations that activate signaling downstream of EGFR. Using a screen to measurereversion of malignant cells into phenotypically nonmalignant cells in 3D gels, we identified FAM83A as a candidatecancer-associated gene capable of conferring resistance to EGFR-TKIs. FAM83A overexpression in cancercells increased proliferation and invasion and imparted EGFR-TKI resistance both in cultured cells and inanimals. Tumor cells that survived EGFR-TKI treatment in vivo had upregulated FAM83A levels. Additionally,FAM83A overexpression dramatically increased the number and size of transformed foci in cultured cells andanchorage-independent growth in soft agar. Conversely, FAM83A depletion in cancer cells caused reversionof the malignant phenotype, delayed tumor growth in mice, and rendered cells more sensitive to EGFR-TKI.Analyses of published clinical data revealed a correlation between high FAM83A expression and breast cancerpatients' poor prognosis. We found that FAM83A interacted with and caused phosphorylation of c-RAF andPI3K p85, upstream of MAPK and downstream of EGFR. These data provide an additional mechanism bywhich tumor cells can become EGFR-TKI resistant.

UR - http://www.scopus.com/inward/record.url?scp=84865982926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865982926&partnerID=8YFLogxK

U2 - 10.1172/JCI60498

DO - 10.1172/JCI60498

M3 - Article

VL - 122

SP - 3211

EP - 3220

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 9

ER -